NCT04798469View on ClinicalTrials.gov

Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

June 30, 2026

Conditions
Opioid UsePainHypogonadism, Male
Interventions
DRUG

Testosterone Undecanoate 250 MG/ML

Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.

DRUG

Placebo

Intramuscular administration of placebo at baseline, weeks 4, and week 14.

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER